Key Points – Key clinical catalysts are ahead for Karyopharm, including FDA engagement and publication plans for its Phase 3 SENTRY myelofibrosis trial, plus an expected mid-2026 readout from the endometrial cancer study XPORT-EC-042. – The SENTRY trial showed a statistically…
gnificant spleen volume response benefit for selinexor plus ruxolitinib, along with an encouraging overall survival signal and no new safety concerns, though the symptom endpoint was not statistically significant. – First-quarter revenue rose to $35.1 million, and Karyopharm reaffirmed full-year 2026 guidance; however, management said underlying XPOVIO demand was weaker year over year due to increased competition. Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in endometrial cancer, while reporting higher first-quarter revenue and reaffirming full-year guidance
On the company’s first-quarter earnings call, President and CEO Richard Paulson said Karyopharm has focused its organization on advancing late-stage clinical programs, maintaining its commercial base in multiple myeloma and managing expenses as it approaches “significant value-creating milestones.” Paulson said the company is now focused on regulatory and scientific engagement for its Phase 3 SENTRY trial in myelofibrosis, preparing for top-line results from XPORT-EC-042 in endometrial cancer and maintaining financial discipline. He said Karyopharm’s current operating plan is expected to fund operations into late in the third quarter of 2026. SENTRY Data Show Spleen Volume Benefit, Survival Signal Chief Medical Officer and Head of Research Reshma Rangwala said Karyopharm remains encouraged by top-line results from SENTRY, which evaluated selinexor in combination with ruxolitinib in myelofibrosis.
The company said the combination produced rapid and sustained spleen volume reductions, with the…